辛伐他汀及缺血预处理对大鼠缺血再灌注心肌损伤中TNF-α、IL-4的影响

EFFECT OF SIMVASTATIN AND ISCHEMIA PRECONDITON ON TNF-α AND IL-4 IN RATS IN VIVO DURING HEART ISCHEMIA AND REPERFUSION INJURY

目的探讨辛伐他汀及缺血预处理对大鼠缺血再灌注心肌损伤中肿瘤坏死因α(tumor necrosis factor-α,TNF-α)、白细胞介素4(interleukin-4,IL-4)的影响。方法雄性Wistar大鼠72只,随机分为4组。①假手术组(Sham,n=9,生理盐水2mL/d,灌胃5周);②缺血再灌注组(ischemia and reperfusion,IR,n=21,生理盐水2mL/d,灌胃5周);③辛伐他汀预处理组(simvastatin,Sim,n=21,5mg·kg^(-1)·d^(-1),灌胃5周);④缺血预处理组(ischemiapreconditon,IPC,n=21,生理盐水2mL/d,灌胃5周)。每组又分缺血30min、再灌注30min、再灌注90min 3个时段。分别测定TNF-α、IL-4,比较2种治疗方法下TNF-α、IL-4的动态变化。结果 IR组TNF-α含量均高于Sim组、IPC组,以再灌注30min和再灌注90min差异有统计学意义(P<0.05)。IR组IL-4含量在再灌注90min时低于Sim组、IPC组中IL-4含量,差异有统计学意义(P<0.05)。各时间段IPC和Sim预处理对TNF-α、IL-4的影响差异无统计学意义(P>0.05)。结论阿托伐他汀或缺血预处理均可抑制缺血再灌心肌损伤中TNF-α表达,增加IL-4表达,从炎症水平上证实2种治疗方法短期内效果无明显差别。

Objective tumor necrosis factor-or （TNF-ot） To study the effect of simvastatin and ischemia preconditon （IPC） and interleukin-4 （IL-4） in rats in vivo during ischemia and reperfusi on on injury of heart. Methods Seventy-two male Wistar rats were randomly divided into four groups ： （1）Sham operated group （ n = 9, normal saline 2mL/d, 5 weeks ） ; （2）ischemia and reperfusion （IR） group （ n = 21, normal saline 2mL/d, 5 weeks） ; （3）simvastatin （Sire） group （ n = 21, simvastatin 5mg·kg-1·d-1 , 5 weeks） ; （4）ischemic precondition （ IPC ） group （ n = 21, normal saline 2mL/d, 5 weeks）. Every group was divided into three subunits： post-ischemia for 30 minutes, reperfusion for 30 minutes and 90 minutes. After surgical procedures,the levels of TNF-α and IL-4 were measured. Results The concentration of TNF-α in IR group was higher than that in Sim group and IPC group, especially at reperfusion for 30 minutes and 90 minutes （P 〈 0.05）. The concentration of IL-4 in IR group at reperfusion for 90 minutes were lower than that in Sim group and IPC group （ P 〈 0.05 ）. No differences of the concentration of TNF-α and IL-4 were found in Sim group and. IPC group （ P 〉 0.05 ）. Conclusion Both of simvastatin and IPC could decrease the concentration of TNF-α and increase the concentration of IL-4 in ischemia and reperfusion injury of heart. At inflammation level, the two treatments proved no significant difference in short-term effect.